Clinical validation Michelson Diagnostics offers VivoSight Dx Pro, a highly validated OCT platform with extensive clinical use across Europe, USA, Asia, and Australia, presenting a strong credibility base for expanding adoption in dermatology clinics and academic centers.

AI driven workflow The integrated VivoAID AI module assists image interpretation and prioritizes clinician attention, enabling faster diagnoses and higher patient throughput — a compelling value proposition for busy dermatology practices and research centers seeking efficiency gains.

Non invasive growth OCT imaging is non-invasive, pain-free, and scar-free, positioning VivoSight as an attractive option for clinics performing recurrent skin assessments, cosmetic research, and wound healing monitoring where patient comfort and repeat imaging matter.

Global footprint With about 90 systems in active clinical use in Germany and a presence in multiple regions, there are clear near-term expansion opportunities in leading dermatology networks, universities, and cosmetics R&D facilities seeking validated OCT capabilities.

Financial potential Current revenue and funding signals indicate a scalable growth path; targeting mid-size to large dermatology groups, academic centers, and cosmetics labs could accelerate adoption and create multi-site deployments leveraging existing validation and case studies.